Results 111 to 120 of about 181,836 (261)

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

Chemistry – A European Journal, EarlyView.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald   +3 more
wiley   +1 more source

Multi-drug resistant Acinetobacter ventilator-associated pneumonia

Lung India, 2010
Background: Ventilator-associated pneumonia (VAP) due to a multi-drug resistant (MDR) Acinetobacter is one of the most dreadful complications, which occurs in the critical care setting.
Shete Vishal, Ghadage Dnyaneshwari, Muley Vrishali, Bhore Arvind   +3 more
doaj  

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

Contezolid in the Treatment of Multidrug-Resistant Tuberculous Meningitis: A Case Report. [PDF]

Clin Case Rep
Wang N, Li X, Yan Q, Su H, Liu Y, Li Y, Yang C, Gu Y, Yan T, Wang Q, Liu X.   +10 more
europepmc   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

The Role of Neonatal Ward Environment as a Reservoir for the Dissemination of Multidrug-Resistant Klebsiella pneumoniae in Algeria. [PDF]

Microbiologyopen
Derkaoui M, Fischer MA, Sebaihia M, Namoune R, Bouheudjeur F, Beloukarif M, Madaoui B, Lopes BS.   +7 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Editorial: Multidrug-resistant Gram-negative bacteria in fragile hosts. [PDF]

Front Microbiol
Montagnani F, Lombardi A, Mularoni A, Docquier JD, Marchesi F.   +4 more
europepmc   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source